| [1] |
Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(2): 104-17. doi: 10.3322/caac.21220
|
| [2] |
Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends--an update[J]. Cancer Epidemiol Biomarkers Prev, 2016, 25(1): 16-27. doi: 10.1158/1055-9965.EPI-15-0578
|
| [3] |
Gunderson LL, Jessup JM, Sargent DJ, et al. Revised TN categorization for colon cancer based on national survival outcomes data[J]. J Clin Oncol, 2010, 28(2): 264-71. doi: 10.1200/JCO.2009.24.0952
|
| [4] |
Diaconescu M, Burada F, Mirea CS, et al. T4 colon cancer-current management[J]. Curr Health Sci J, 2018, 44(1): 5-13.
|
| [5] |
Arredondo J, Baixauli J, Pastor C, et al. Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery[J]. Clin Transl Oncol, 2017, 19(3): 379-85. doi: 10.1007/s12094-016-1539-4
|
| [6] |
Morton U, Seymour M, Magill L, et al. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial[J]. Lancet Oncol, 2012, 13(11): 1152-60. doi: 10.1016/S1470-2045(12)70348-0
|
| [7] |
Arredondo J, Gonzalez I, Baixauli J, et al. Tumor response assessment in locally advanced colon cancer after neoadjuvant chemotherapy[J]. J Gastrointest Oncol, 2014, 5(2): 104-11.
|
| [8] |
Dehal A, Graff B, Vuon G, et al. Neoadjuvant chemotherapy improves survival in patients with clinical T4b colon cancer[J]. J Gastrointest Surg, 2018, 22(2): 242-9. doi: 10.1007/s11605-017-3566-z
|
| [9] |
Hawkins AT, Ford MM, Geiger TM, et al. Neoadjuvant radiation for clinical T4 colon cancer: a potential improvement to overall survival[J]. Surgery, 2019, 165(2): 469-75. doi: 10.1016/j.surg.2018.06.015
|
| [10] |
Cukier M, Smith AJ, Milot L, et al. Neoadjuvant chemoradiotherapy and multivisceral resect ion for primary locally advanced adherent colon cancer: a single institution experience[J]. Eur J Surg Oncol, 2012, 38(8): 677-82. doi: 10.1016/j.ejso.2012.05.001
|
| [11] |
Huang CM, Huang MY, Ma CJ, et al. Neoadjuvant FOLFOX chemotherapy combined with radiotherapy followed by radical resection in patients with locally advanced colon cancer[J]. Radiat Oncol, 2017, 12(1): 48-59. doi: 10.1186/s13014-017-0790-3
|
| [12] |
Qiu B, Ding PR, Cai L, et al. Outcomes of preoperative chemoradiotherapy followed by surgery in patients with unresectable locally advanced sigmoid colon cancer[J]. Chin J Cancer, 2016, 35(1): 65-76. doi: 10.1186/s40880-016-0126-y
|
| [13] |
Benson AB, Venook AP, Lynette C, et al. Colon cancer, version 1, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2017, 15(3): 370-98. doi: 10.6004/jnccn.2017.0036
|
| [14] |
Hohenberger W, Weber K, Matzel K, et al. Standardized surgery for colonic cancer: complete mesocolic excision and central ligation--technical notes and outcome[J]. Colorectal Dis, 2009, 11(4): 354-64. doi: 10.1111/j.1463-1318.2008.01735.x
|
| [15] |
Mohan HM, Evans MD, Larkin JO, et al. Multivisceral resection in colorectal cancer: a systematic review[J]. Ann Surg Oncol, 2013, 20(9): 2929-36. doi: 10.1245/s10434-013-2967-9
|
| [16] |
Lopez-Cano M, Manas MJ, Hermosilla E, et al. Multivisceralresection for colon cancer:analysis of prognostic factors[J]. Dig Surg, 2010, 27(3): 238-45. doi: 10.1159/000276974
|
| [17] |
Luna-Perez P, Rodriguez-Ramirez SE, De la Barrera MG, et al. Multivisceral resection for colon cancer[J]. J Surg Oncol, 2002, 80(5): 100-4.
|
| [18] |
Shukla PJ, Trencheva K, Merchant CA, et al. Laparoscopic resection of T4 colon cancers: is it feasible[J]. Dis Colon Rectum, 2015, 58(1): 25-31. doi: 10.1097/DCR.0000000000000220
|
| [19] |
Klaver C, Kappen TM, Borstlap W, et al. Laparoscopic surgery for T4 colon cancer: a systematic review and meta-analysis[J]. Surg Endosc, 2017, 31(12): 4902-12. doi: 10.1007/s00464-017-5544-7
|
| [20] |
Biagi JJ, Raphael MJ, Mackillop WJ, et al. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis[J]. JAMA, 2011, 305(22): 2335-42. doi: 10.1001/jama.2011.749
|
| [21] |
Jeong WK, Shin JW, Baek SK. Oncologic outcomes of early adjuvant chemotherapy initiation in patients with stage Ⅲ colon cancer[J]. Annals Surg Treat Res, 2015, 89(3): 124-30. doi: 10.4174/astr.2015.89.3.124
|
| [22] |
Mouradov D, Domingo E, Gibbs P, et al. Survival in stage Ⅱ/Ⅲ colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations[J]. Am J Gastroenterol, 2013, 108(11): 1785-93. doi: 10.1038/ajg.2013.292
|
| [23] |
André T, Iveson T, Labianca R, et al. The IDEA (international duration evaluation of adjuvant chemotherapy) collaboration: prospective combined analysis of phase Ⅲ trials investigating duration of adjuvant therapy with the FOLFOX (FOLFOX4 or modifid FOLFOX6) or XELOX (3 versus 6 months) regimen for patients with stage Ⅲ colon cancer: trial design and current status[J]. Curr Colorectal Cancer Rep, 2013, 9(7): 261-9.
|
点击查看大图
下载:
